These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31200359)

  • 1. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
    Gbolahan O; Hashemi-Sadraei N; O'Neil B
    J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
    Das S; Allen A; Berlin J
    Clin Colorectal Cancer; 2020 Jun; 19(2):137-140. PubMed ID: 32146081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
    Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
    J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment of advanced or recurrent biliary tract cancer.
    Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
    Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting cholangiocarcinoma.
    Mertens JC; Ilyas SI; Gores GJ
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it Possible to Increase Survival of Patients with Intrahepatic Cholangiocarcinoma? A Case Report.
    Oguz S; Kucukaslan H; Topaloglu S; Ones T; Baltacioglu F; Cobanoglu U; Calik A
    J Gastrointest Cancer; 2021 Mar; 52(1):342-346. PubMed ID: 32617830
    [No Abstract]   [Full Text] [Related]  

  • 7. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
    Zhang Q; Lou Y; Bai XL; Liang TB
    World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
    Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
    Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Inflammation and Hepatobiliary Cancers.
    Leone V; Ali A; Weber A; Tschaharganeh DF; Heikenwalder M
    Trends Cancer; 2021 Jul; 7(7):606-623. PubMed ID: 33674229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
    Mou H; Yu L; Liao Q; Hou X; Wu Y; Cui Q; Yan N; Ma R; Wang L; Yao M; Wang K
    BMC Cancer; 2018 Nov; 18(1):1105. PubMed ID: 30419854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.
    Ma L; Hernandez MO; Zhao Y; Mehta M; Tran B; Kelly M; Rae Z; Hernandez JM; Davis JL; Martin SP; Kleiner DE; Hewitt SM; Ylaya K; Wood BJ; Greten TF; Wang XW
    Cancer Cell; 2019 Oct; 36(4):418-430.e6. PubMed ID: 31588021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
    Chen WX; Li GX; Hu ZN; Zhu P; Zhang BX; Ding ZY
    Medicine (Baltimore); 2019 Nov; 98(45):e17832. PubMed ID: 31702638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.
    Sui M; Li Y; Wang H; Luo Y; Wan T; Wang X; Hu B; Cheng Y; Lv X; Xin X; Xu Q; Wang G; Lu S
    J Immunother Cancer; 2019 May; 7(1):125. PubMed ID: 31064408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival after multimodal therapy in a patient demonstrating intrahepatic cholangiocarcinoma with hilar invasion and intrahepatic metastases.
    Morinaga S; Yamamoto Y; Sugano N; Wada H; Shiozawa M; Akaike M; Sugimasa Y
    Int J Clin Oncol; 2008 Aug; 13(4):361-4. PubMed ID: 18704639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period.
    Yamazaki S; Kubota K; Shimizu A; Notake T; Umemura K; Kamachi A; Goto T; Tomida H; Yamashita N; Sato M; Kanno H; Soejima Y
    Intern Med; 2024 Apr; 63(8):1105-1112. PubMed ID: 37779076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
    Raggi D; Necchi A; Giannatempo P
    Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.
    Alnaggar M; Xu Y; Li J; He J; Chen J; Li M; Wu Q; Lin L; Liang Y; Wang X; Li J; Hu Y; Chen Y; Xu K; Wu Y; Yin Z
    J Immunother Cancer; 2019 Feb; 7(1):36. PubMed ID: 30736852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
    Koido S; Kan S; Yoshida K; Yoshizaki S; Takakura K; Namiki Y; Tsukinaga S; Odahara S; Kajihara M; Okamoto M; Ito M; Yusa S; Gong J; Sugiyama H; Ohkusa T; Homma S; Tajiri H
    Anticancer Res; 2014 Nov; 34(11):6353-61. PubMed ID: 25368235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.